Your trusted source for investing success

Tag: clinical trials

Looking for Cannabis Stocks?

Read our report to find market data, important news and stocks to watch!
 
3D Signatures Inc. Announces Positive Topline Results of Development Trial Assessing its Telo-HL™ Test for Hodgkin’s Lymphoma

3D Signatures Inc. Announces Positive Topline Results of Development Trial Assessing its Telo-HL™ Test for Hodgkin’s Lymphoma

3D Signa­­­­­­tures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the “Company” or “3DS”) is pleased to announce that a preliminary third-party analysis of the trial data for Telo-HLTM, 3DS’ test in development for Hodgkin’s lymphoma (HL), shows that the Company’s TeloViewTM platform is able to distinguish, with a high degree of statistical significance,

Cytokinetics Reports Fourth Quarter 2017 Financial Results

Cytokinetics (Nasdaq:CYTK) reported financial results for the fourth quarter of 2017. Net loss for the fourth quarter was $40.5 million, or $0.75 per basic share and diluted share, respectively, compared to net income for the same period in 2016 of $7.2 million, or $0.18 and $0.16 per basic and diluted

Moleculin Announces Pricing of $9 Million Registered Direct Offering

Moleculin Biotech (NASDAQ: MBRX) a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, announced that it has entered into a definitive agreement with institutional investors

Evoke Announces Discovery of Sex-Based Pharmacokinetic Differences for Gimoti

Evoke Pharma (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) d­­iseases, today announced additional findings from its comparative exposure pharmacokinetic (PK) trial for Gimoti™, the Company’s novel nasal spray delivery of metoclopramide for the treatment of symptoms associated with gastroparesis. Further analysis of the PK data by sex

Tetraphase Announces Top-Line Results from IGNITE3 Phase 3 Clinical Trial of Eravacycline

Tetraphase Pharmaceuticals (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that its IGNITE3 clinical trial evaluating the efficacy and safety of once-daily intravenous (IV) eravacycline compared to ertapenem for the treatment of patients with complicated urinary tract infections (cUTI) did

Sorrento’s and Yuhan’s Joint Venture, ImmuneOncia, receives Approval to begin clinical trial of Anti-PD-L1

Yuhan (KRX:000100.KS) and Sorrento Therapeutics (Nasdaq:SRNE) announce that the South Korean Ministry of Food and Drug Safety has approved ImmuneOncia Therapeutics’ (51% Yuhan/49% Sorrento joint venture formed in March 2016) IND for the initiation of clinical trials for Sorrento-discovered anti-PD-L1 monoclonal antibody STI-A1015 (IMC-001), which is exclusively licensed to ImmuneOncia

2018 Genetics Market Report


Find out what to watch for in the world of genetics investing.


Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
MYM Nutraceuticals CEO: MYM More than Just a Cannabis Grower

URL: https://investingnews.com/daily/resource-investing/agriculture-investing/cannabis-investing/mym-nutraceuticals-rob-gietl/